GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alexza Pharmaceuticals Inc (OTCPK:ALXA) » Definitions » Preferred Stock

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Preferred Stock : $0.00 Mil (As of Mar. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Alexza Pharmaceuticals Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Alexza Pharmaceuticals's preferred stock for the quarter that ended in Mar. 2016 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Alexza Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 was $73.89 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Alexza Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2016 was $-3.42.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Alexza Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2016 was $-0.16.


Alexza Pharmaceuticals Preferred Stock Historical Data

The historical data trend for Alexza Pharmaceuticals's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexza Pharmaceuticals Preferred Stock Chart

Alexza Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alexza Pharmaceuticals Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Alexza Pharmaceuticals Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Alexza Pharmaceuticals  (OTCPK:ALXA) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Alexza Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2016 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Alexza Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2016 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Alexza Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexza Pharmaceuticals Preferred Stock Related Terms

Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Gordon Ringold director 325 EAST MIDDLEFIELD AVENUE, MOUNTAIN VIEW CA 94043
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Thomas Braxton King director, officer: President & CEO 91 JAMES AVENUE, ATHERTON CA 94027
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark K Oki officer: Former SVP, CFO, Secretary C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Robert A Lippe officer: EVP, Operations & COO C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
James V Cassella director, officer: Former EVP, R&D and CSO 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Samuel D Colella other: Former Director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Alan D Frazier director
Symphony Capital Gp, L.p. 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Harri V Taranto 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Gp, Llc 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Capital Partners Lp 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, NEW YORK NY 10022
Mark Kessel 10 percent owner, other: See Footnote 2 and Remarks 950 PARK AVE APT. 11A, NEW YORK NY 10028

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Headlines